GSK Can Seize Chance In Anemia After Rivals Rejected But FDA Caution Will Remain
Daprodustat Filing Accepted In US
Executive Summary
GSK’s drug is the first in the class to show non-inferiority to standard therapy in safety, but the data still contains areas of doubt.